Yazan: admin Tarih: Şub 25th, 2010 | Kategori::
Paraoxonase
Turk Kardiyol Dern Ars. 2009 Oct;37(7):473-8.
Taşkiran P, Cam SF, Sekuri C, Tüzün N, Alioğlu E, Altintaş N, Berdeli A.
Department of Medical Biology and Genetics, Medicine Faculty of Celal Bayar University, Manisa, Turkey.
OBJECTIVES: Paraoxonase (PON1) is a high-density lipoprotein (HDL)-associated esterase that hydrolyses lipoperoxides. PON1 serves as a protective factor against oxidative modification of LDL, suggesting that it may play an important role in the prevention of atherosclerotic process. Research has focused on two polymorphisms: leucine (L allele) to methionine (M allele) substitution at codon 55, and glutamine (A allele) to arginine (B allele) substitution at codon 192. STUDY DESIGN: We examined amino acid changes at codon 55 and 192 in the PON1 gene by polymerase chain reaction and using restriction enzymes in 120 patients (92 men, 28 women; mean age 48.2+/-4.3 years) with premature coronary artery disease (CAD) and in 102 healthy subjects (80 men, 22 women; mean age 46.8+/-5.2 years) with no history of CAD and a normal electrocardiogram. RESULTS: Distribution of genotypes in the patient and control groups at codon 55 were 6.7% and 4.9% for MM, 46.7% and 29.4% for LM, 46.7% and 65.7% for LL, respectively. The frequency of genotypes at codon 192 were as follows: 4.2% and 2% for RR, 40% and 35.3% for QR, and 55.8% and 62.8% for QQ, respectively. While the frequency of PON1 55M allele was higher in the CAD group (0.3 vs. 0.2), PON1 192R allele frequency did not differ (p>0.05). There was a significant relationship between the PON1 M/L55 polymorphism and CAD (p=0.017), whereas the R/Q192 polymorphism was not associated with CAD (p=0.445). CONCLUSION: These data suggest that the PON1 M/L55 polymorphism shows a significant relationship with CAD and the Q/R192 polymorphism is not a major risk factor causing susceptibility to CAD in our population.
Yazan: admin Tarih: Şub 3rd, 2010 | Kategori::
Paraoxanase gene
Turk Kardiyol Dern Ars. 2009;37(7):473-478.
Taşkıran P, Cam SF, Sekuri C, Tüzün N, Alioğlu E, Altıntaş N, Berdeli A.
Department of Medical Biology and Genetics, Medicine Faculty of Celal Bayar University, Manisa, Turkey.
OBJECTIVES: Paraoxonase (PON1) is a high-density lipoprotein (HDL)-associated esterase that hydrolyses lipoperoxides. PON1 serves as a protective factor against oxidative modification of LDL, suggesting that it may play an important role in the prevention of atherosclerotic process. Research has focused on two polymorphisms: leucine (L allele) to methionine (M allele) substitution at codon 55, and glutamine (A allele) to arginine (B allele) substitution at codon 192. STUDY DESIGN: We examined amino acid changes at codon 55 and 192 in the PON1 gene by polymerase chain reaction and using restriction enzymes in 120 patients (92 men, 28 women; mean age 48.2+/-4.3 years) with premature coronary artery disease (CAD) and in 102 healthy subjects (80 men, 22 women; mean age 46.8+/-5.2 years) with no history of CAD and a normal electrocardiogram. RESULTS: Distribution of genotypes in the patient and control groups at codon 55 were 6.7% and 4.9% for MM, 46.7% and 29.4% for LM, 46.7% and 65.7% for LL, respectively. The frequency of genotypes at codon 192 were as follows: 4.2% and 2% for RR, 40% and 35.3% for QR, and 55.8% and 62.8% for QQ, respectively. While the frequency of PON1 55M allele was higher in the CAD group (0.3 vs. 0.2), PON1 192R allele frequency did not differ (p>0.05). There was a significant relationship between the PON1 M/L55 polymorphism and CAD (p=0.017), whereas the R/Q192 polymorphism was not associated with CAD (p=0.445). CONCLUSION: These data suggest that the PON1 M/L55 polymorphism shows a significant relationship with CAD and the Q/R192 polymorphism is not a major risk factor causing susceptibility to CAD in our population.
Yazan: admin Tarih: Ara 5th, 2008 | Kategori::
Thyroid cancer(Tiroid kanseri)
J Endocrinol Invest. 2008 Sep;31(9):750-4.
Department of Endocrinology and Metabolism Disease, Ege University Medical School, Bornova, Izmir, Turkey. drmerdogan61@yahoo.com
OBJECTIVE: Interleukin-10 (IL-10) is a major anti-inflammatory cytokine that plays a crucial role in the regulation of the immune system. Chronic inflammation has been reported to be a risk factor for thyroid neoplasia. The propensity to mount an inflammatory response is modified by germ line variation in cytokine and other inflammation-related genes. We hypothesized that a proinflammatory genotype would be positively associated with thyroid cancer. We aimed to evaluate the relation between the genotypic and allelic frequencies of the IL-10(-1082 G/A), IL-10(-592 A/C), and IL-10(-819 C/T) polymorphisms, and their association with the risk of developing papillary thyroid cancer (PTC) in the Turkish population. RESEARCH DESIGN AND METHODS: Forty-two patients with PTC and 113 healthy controls were included in this study. The diagnosis of PTC was confirmed by histopathologic examination after surgery. The evaluation of genotype for IL-10 gene polymorphism was performed using PCR-restriction fragment length polymorphism method. RESULTS: Statistically significant difference IL-10(-1082 G/A) gene polymorphism was determined between 2 (PTC and control) groups. No difference was determined with respect to IL-10(-592 A/C) and IL-10(-819 C/T) gene polymorphisms, and IL-10(-1082 G/A), IL-10(-592 A/C), and IL-10(-819 C/T) allele frequencies of participating between the control group and the patients with PTC (p>0.05). CONCLUSIONS: The polymorphism of IL-10(-1082 G/A) gene was significantly associated with the occurrence of PTC. Such studies will contribute significantly to our understanding of the biological role of IL-10(-1082 G/A) gene polymorphism in PTC development. In conclusion, IL-10(-1082 G/A) gene polymorphism may affect the survival of papillary thyroid carcinoma.
Yazan: admin Tarih: Ağu 31st, 2008 | Kategori::
polymorphisms
Turkiye Klinikleri J Med Sci 2004, 24:573-578
Dr. Nurten ERDAL,a Dr. M. Emin ERDAL,b Dr. Kaan SAVAŞOĞLU,b Tuba GÖKDOĞANb
aBiyofizik AD, bTıbbi Biyoloji ve Genetik AD, Mersin Üniversitesi Tıp Fakültesi, MERSİN
Objective: X-ray repair cross-complementing (XRCC1) is one of the genes responsible for the DNA repair mechanism. It plays an important role in the protection of the integrity of the genome and in the development of mutations in hereditary genetic disease and cancer. The XRCC1 gene codes proteins which play a role in the repair of DNA strand breaks caused by active oxygen, ionization and alkylating agents. Functional polymorphism of the XRCC1 gene is a contributing factor for changes in the DNA repair mechanism, which is a risk factor for cancer.
Material and Methods: Codon 194 (Arg→Trp) and codon 399 (Arg→Gln) are functional polymorphisms in the XRCC1 gene. These polymorphisms were determined by Polymerase Chain Reaction (PCR) and Restriction Fragment Length Polymorphism (RFLP) in unrelated 75 healty persons. These results were compared with other related investigation results.
Results: Frequencies of Arg and Trp alleles of codon 194 were shown to be 0.94 and 0.06, respectively. However, frequencies of Arg and Gln alleles of codon 399 were 0.65 and 0.35.
Conclusion: With regard to Arg194Trp functional polymorphisms of the XRCC1 gene, our results of allele frequencies are similar to those found in related investigations in American (caucasian) and Colombian populations, but different from others in Taiwanese, American (African-American) and Chinese populations. The other XRCC1 gene polymorphism examined, Arg399Gln, manifested frequencies similar to those found in investigations in Italian, American (caucasian), Finnish and Colombian populations; however, our results are different from those involving Taiwanese, American (African-American), Colombian, Asian and Chinese populations. The alleles at risk appear to vary in different populations and according to cancer type. Therefore, it is very important to determine those alleles exhibiting a heightened cancer risk in our population.
Keywords: Genes, polymorphism, XRCC1 protein
Turkiye Klinikleri J Med Sci 2004, 24:573-578
